mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer
Written by
Cancer Network
Published
0
comments
0
min
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.